{
}
UBS has lowered its price target for Eli Lilly from $1,100 to $1,050 while maintaining a Buy rating, following strong Q1 2025 results overshadowed by concerns over CVS Caremark favoring Wegovy over Zepbound and lower expectations for obesity drug Orfo. Despite a 10.22% stock decline, analysts believe the market reaction may be exaggerated, noting Eli Lilly's solid fundamentals and a strong dividend history. The company reported a 45% revenue increase year-over-year but missed EPS guidance, prompting a revision of its full-year earnings outlook.
UBS has lowered its price target for Eli Lilly from $1,100 to $1,050 while maintaining a Buy recommendation, despite a 10.22% stock decline over the past week. Concerns arose from CVS Caremark favoring Novo's Wegovy over Zepbound and lower-than-expected results for the obesity treatment orfo. Eli Lilly reported a 45% revenue increase year-on-year but missed EPS guidance, prompting a negative market reaction, while analysts from Cantor Fitzgerald and Leerink Partners remain optimistic about the company's long-term potential.
UBS has lowered its price target for Eli Lilly from $1,100 to $1,050 while maintaining a Buy rating, following a strong first-quarter performance overshadowed by concerns over competitive pressures from CVS Caremark favoring Novo's Wegovy over Zepbound. Despite a 10.22% stock decline, analysts believe the market reaction may be excessive, noting Eli Lilly's solid fundamentals and ongoing revenue growth. The company reported a 45% year-over-year revenue increase but missed EPS forecasts, prompting a revised earnings outlook for 2025.
UBS analyst Trung Huynh has lowered the price target for Eli Lilly (LLY) to $1,050 from $1,100 while maintaining a Buy rating. Concerns over GLP-1 pricing, lower expectations for orfo obesity, and the withdrawal of tirzepatide's HFpEF indication contributed to a recent stock decline of 11%. Despite these issues, the analyst believes the market reaction is an overreaction, citing low covered lives on CVS Caremark and potential for improved expectations in future studies.
Eli Lilly will participate in the Bank of America Securities 2025 Healthcare Conference on May 15, 2025, with Executive Vice President and CFO Lucas Montarce leading a fireside chat at 11:40 a.m. Eastern time. Investors can access a live webcast on Lilly's investor website, and a replay will be available for 90 days post-event, highlighting the company's commitment to transparency and engagement in the healthcare sector.
Eli Lilly and Company will participate in the Bank of America Securities 2025 Healthcare Conference on May 15, 2025. Lucas Montarce, the executive vice president and CFO, will engage in a fireside chat at 11:40 a.m. ET, with a live audio webcast available on Lilly's investor website. A replay will be accessible for approximately 90 days.
Eli Lilly and Company will participate in the Bank of America Securities 2025 Healthcare Conference on May 15, 2025, featuring CFO Lucas Montarce in a fireside chat at 11:40 a.m. ET. A live audio webcast will be accessible on Lilly's investor website, with a replay available for 90 days. Lilly continues to advance significant health solutions, focusing on diabetes, obesity, Alzheimer's, immune disorders, and challenging cancers, while ensuring accessibility and affordability of its medicines.
UBS analyst Trung Huynh has lowered Eli Lilly's price target from $1,100 to $1,050 while maintaining a Buy rating, citing excessive stock decline despite strong GLP sales. Analysts project an average target of $995.43, indicating a potential upside of 25.35% from the current price of $794.10. In Q1 2025, Eli Lilly reported a 45% revenue increase, driven by Mounjaro and Zepbound, alongside significant pipeline advancements and a commitment to over $50 billion in US manufacturing investments since 2020.
As May begins, attention turns to key UK economic data, including manufacturing and bank lending figures. Lloyds Banking Group shares have surged by a third this year, while the London Stock Exchange Group approaches its all-time high, contrasting with Whitbread's 15% decline. After US markets close, earnings reports from Apple and Amazon will be scrutinized for insights on tariff impacts.
As May begins, attention turns to key UK economic data, including manufacturing and bank lending figures. Lloyds Banking Group shares have surged by a third this year, while the London Stock Exchange Group approaches its all-time high. In contrast, Whitbread's shares have fallen 15% amid tourism sector challenges. Later, Apple and Amazon will report earnings, with a focus on the impact of US tariffs.
Eli Lilly and Company
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers eli lilly price target but maintains buy recommendation
18:44 02.05.2025
ubs lowers eli lilly price target but maintains buy recommendation
18:44 02.05.2025
ubs lowers eli lilly price target but maintains buy rating amid concerns
18:43 02.05.2025
Eli Lilly price target reduced to 1050 by UBS amid market concerns
United States Dollar
Novo Nordisk A/S
CVS Health Corporation
Eli Lilly and Company
USA
Trung Huynh
Show more
17:59 02.05.2025
eli lilly to present at bank of america healthcare conference 2025
16:16 02.05.2025
lilly to participate in bank of america securities healthcare conference 2025
16:01 02.05.2025
Eli Lilly CFO to Discuss Strategies at Bank of America Healthcare Conference
16:00 02.05.2025
eli lilly reports strong revenue growth despite price target reduction by analyst
15:45 02.05.2025
UK economic data and corporate earnings in focus for May 1
British Pound Sterling
United States Dollar
Amazon.com, Inc.
Lloyds Banking Group plc
London Stock Exchange Group plc
Eli Lilly and Company
McDonald's Corporation
Apple Inc.
Whitbread plc
Mastercard Inc
GBR
Show more
07:00 01.05.2025
UK market updates as Lloyds and London Stock Exchange report earnings
British Pound Sterling
Euro
United States Dollar
McDonald's Corporation
Amazon.com, Inc.
Apple Inc.
Eli Lilly and Company
Mastercard Inc
GBR
USA
Show more
06:00 01.05.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: